Facile Assay for the Cancer-Linked Peptidylarginine Deiminase


The protein peptidylarginine deiminase (PAD) plays an important role in the life cycle of normal human cells, and the deregulation of PADs has been implicated in the development of many diseases. The ability to measure this in a facile manner could prove very useful in the development of drug therapies.  This technology was developed to measure PAD and is unique as it uses a small molecule with affinity for PADs, conjugated to a fluorescent label. The entire process can be performed in a half hour or less and is expected to be easier and more accurate that antibody-bases ELISA tests that require more reagents and manual steps.  In addition to its application in drug development, this assay could also play a role in monitoring tumor progression. The link between PADs and cancer is strengthened by recent findings showing that treatment of cell lines and mice with PAD inhibitors significantly suppresses tumor growth and, interestingly, inflammatory symptoms. 


Lehigh TechID# 121112-01



The most likely market is companion diagnostics for cancer and autoimmune disease therapeutics. Companion diagnostics are diagnostic tests that are linked to a particular drug/therapy and the market is growing due to developments in biomarkers and the unmet need in specific therapeutic areas.  The global life science and analytical reagents market was valued at over $40 billion in 2011 and is expected to reach almost $60 billion by 2016.



Lehigh University is currently looking for a corporate partner to further development. 


App Type Country Serial No. Patent No. File Date Issued Date Expire Date
Provisional [PR] United States 61/767,555 2/21/2013   2/21/2014
Life Sciences
For Information, Contact:
Alan Snyder
VP, Research & Grad Programs
Lehigh University
Marcos Pires
Life Sciences
Lipoprotein Metabolism